

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
04 AUG 25 PM 3:06

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Alston & Bird LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 601 Pennsylvania Ave., NW, 10th Floor, Washington, DC 20004-2601			
3. Principal Place of Business (if different from line 2) City: Atlanta State/Zip (or Country) GA/30309-3424			
4. Contact Name Jonathan M. Winer	Telephone (202) 756-3342	E-mail (optional) jwiner@alston.com	5. Senate ID # 11
7. Client Name <input type="checkbox"/> Self Aventis Pharmaceuticals			6. House ID # 31

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) OR Year End (July 1-D

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____

11. No Lobbyi

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>20,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$2</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for descriptor</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA def</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section Internal Revenue Code</p>
--	---

Signature



Signature J. M. Winer

Printed Name and Title

Jonathan M. Winer, Partner

LD-2 (REV. 6/98)

Registrant Name Aiston & Bird LLP Client Name Aventis Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Part B payments for drugs and biologicals; implementation of new Part D benefit.

17. House(s) of Congress and Federal agencies contacted Check if None


Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Colin Roskey	Senate Finance Comm-Health Policy Adv & Cnsl
M. Lynn Sykes	
Thomas A. Scully	Centers for Medicare & Medicaid Svcs-Admin
Jennifer L. Butler	
Erin Darling	
Alicia Ziemiecki	
David Hebert, Marc Scheineson	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA, Strasbourg, France owns 100% of Aventis Pharmaceuticals.

Signature  Date 8/2/2009

Printed Name and Title U Jonathan M. Winer, Partner

Form LD-2 (Rev. 6/98)

P:

Registrant Name Alston & Bird LLP Client Name Aventis Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Medicare Part B payments for drugs and biologicals; implementation of new Part D benefit.

17. House(s) of Congress and Federal agencies contacted

Check if None

Department of Health and Human Services


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Colin Roskey	Senate Finance Comm-Health Policy Adv & Cnsl
M. Lynn Sykes	
Thomas A. Scully	Centers for Medicare & Medicaid Svcs-Admin
Jennifer L. Butler	
Erin Darling	
Alicia Ziemiecki	
David Hebert, Marc Scheineson	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Aventis SA, Strasbourg, France owns 100% of Aventis Pharmaceuticals.

Signature  Date 8/2/2007

